Solving Critical Global Healthcare Challenges Through Focused MedTech Investing

About

One Six 8 Ventures is a venture capital firm partnering with exceptional entrepreneurs to build transformative early-stage MedTech companies. Our core mission is to back innovations that fundamentally improve patient outcomes while creating substantial market value.


Our investment focus is clear: early-stage Medical Technology. We maintain a disciplined approach, targeting specific sub-sectors where innovation can drive significant clinical and market impact.


​Built over nearly two decades, our team offers a distinct advantage: direct experience as founders, operators, and executives within VC-backed MedTech and life sciences. This allows us to conduct deep, multi-faceted due diligence and actively partner with founders post-investment. We provide hands-on strategic and operational guidance, leveraging our experience to help companies navigate growth, manage risk effectively, preserve capital, and achieve market leadership.​

THE TEAM

The One Six 8 Ventures team comprises seasoned operators and executives with deep roots in scaling VC-backed life sciences companies over nearly two decades. We act as hands-on partners to our portfolio founders, providing strategic guidance and support grounded in extensive industry experience. Learn more about our team below:

Judyanna Yu

Managing Partner
CFO, Providence Therapeutics
CFO & COO, Restem Biotech 
CFO, Biochem Group
VP Corporate Finance, Cerecin
Health business entrepreneur​
​Previous: Manning Elliott LLP, KPMG, Auditor General of Alberta
Board, BioAlberta
Board, Pharmsky Research

Charles Stacey, MD, MBA

Partner
President & CEO, Cerecin
Inventages Venture Capital ($1.5B AUM)
Orthopaedics and trauma surgeon in London
Medtech entrepreneur
​Board of Governors, Accreditation Council for Medical Affairs
​

Ankang Li, PhD, JD, CFA

Advisor
CFO, CSO and Executive Director, Brii Biosciences
CEO, TSB Therapeutics
CFO, Terns Pharmaceutical
​Executive Director, Healthcare Investment Banking, Goldman Sachs,
BD Director, Merck,
Associate at Davis Polk, Ropes & Gray

Xi Qiao, MSc

Principal
Head of BD Commercial Evaluation, Fosun Pharma,
Consultant at Boston Consulting Group,
Pricing and Market Access Manager, AstraZeneca,
​Health & TMT Senior Consultant, Ernst & Young